Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

The clinical use of MRI in patients with multiple sclerosis (MS) has advanced markedly over
the past few years. Technical improvements and continuously emerging data from clinical …

Background Treatment of mild-moderate Alzheimer's disease (AD) subjects (N= 119) for 52
weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates …

The amyloid hypothesis suggests that the progressive accumulation and deposition of
central nervous system (CNS) amyloid with aging is the proximate cause of Alzheimer's …

Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active
relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In …

Overactivation of microglia is associated with most neurodegenerative diseases. In this
study we examined whether PET-measurable innate immune cell activation predicts multiple …

Background:'No evidence of disease activity'(NEDA), defined as absence of magnetic
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …

Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying
degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to …

Objective To assess whether it is feasible to establish specific cut-off values able to
discriminate 'physiological'or 'pathological'brain volume rates in patients with multiple …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …